Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …

Although plant biotechnology has been widely investigated for the production of clinical‐
grade monoclonal antibodies, no antibody products derived from transgenic plants have yet …

HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was
largely ineffective in pre-clinical and clinical settings and was therefore abandoned …

Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-
prone HIV-1 replication leads to the production of drug-resistant viral variants …

Summary VRC-HIVMAB060-00-AB (VRC01) is a broadly neutralizing HIV-1 monoclonal
antibody (mAb) isolated from the B cells of an HIV-infected patient. It is directed against the …

To determine the protective potential of the humoral immune response against HIV-1 in vivo
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …

Monoclonal antibodies (mAbs) have long provided powerful research tools for virologists to
understand the mechanisms of virus entry into host cells and of antiviral immunity. Even so …

Passive immunization with broadly neutralizing antibodies (bnAbs) is a promising approach
to reduce the 1.7 million annual human immunodeficiency virus (HIV) infections globally …

The continuous increase in the number of approved monoclonal antibody (mAb)-based
therapy suggests that mAbs, and their derivatives, will continue to be the focus of the …

Passive transfer of antibodies has long been considered a potential treatment modality for
infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV …